OrgaNext
| Private[1] | |
| Industry | pharmaceutical industry |
| Founded | 2007 |
| Founder | Marjanne Prins |
| Headquarters | Arnhem, The Netherlands |
Key people | Marjanne Prins (CEO) |
Number of employees | 4 |
|
Footnotes / references Headquarters[2] | |
OrgaNext is a Dutch pharmaceutical company established in 2007 with no marketed products as of 2015.[2] The company was founded by Marjanne Prins, who also serves as the chief executive officer.[2] As of the end of 2014, the company had four employees, all former employees of Organon International who left the company when it was acquired by Schering-Plough in 2007.[2] The focus of the company is the development of a treatment for age-related muscle atrophy, specifically a "low-dose, short-term Recovery Booster therapy, a combination of nandrolone decanoate and Vitamin D3 (NDD)" for administration to victims of hip fractures.[1][2] In 2011, the company received a WIPO patent for a general treatment for "frailty" of which NDD was a specific instance.[3]
OrgaNext was established with seed financing of US$3,200,000 and was seeking, as of late 2014, an infusion of US$31,000,000 through Series A and Series B venture capital funds.[2]
References
- 1 2 3 "OrgaNext Research: Addition of Vitamin D Improves Safety Profile of Nandrolone". Biotech Week. 11 July 2012. Retrieved 21 October 2016 – via Highbeam Research. (Subscription required (help)).
- 1 2 3 4 5 6 Kobertstein, Wayne (December 2014). "OrgaNext". Companies to watch. Life Science Leader. 6 (12): 14. (Registration required (help)).
- ↑ "WIPO Assigns Patent to OrganNext Research for "Method of Treating Frailty" (Dutch Inventors)". US Fed News Service. 5 March 2011. Retrieved 21 October 2016 – via HighBeam Research. (Subscription required (help)).